Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice
- 23 May 2013
- journal article
- Published by Elsevier BV in European Journal of Pharmacology
- Vol. 715 (1-3), 246-255
- https://doi.org/10.1016/j.ejphar.2013.05.014
Abstract
No abstract availableThis publication has 34 references indexed in Scilit:
- Type 2 Diabetes Mellitus-Induced Hyperglycemia in Patients with NAFLD and Normal LFTs: Relationship to Lipid Profile, Oxidative Stress and Pro-Inflammatory CytokinesScientia Pharmaceutica, 2011
- SGLT2 inhibition — a novel strategy for diabetes treatmentNature Reviews Drug Discovery, 2010
- Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weightDiabetes, Obesity and Metabolism, 2010
- Attenuation of oxidative stress in streptozotocin-induced diabetic rats by Eucalyptus globulusIndian Journal of Clinical Biochemistry, 2009
- Hyperglycemia and the Pathobiology of Diabetic ComplicationsPublished by S. Karger AG ,2008
- Diet, obesity and diabetes: a current updateClinical Science, 2006
- Nonalcoholic fatty liver disease: is all the fat bad?Internal Medicine Journal, 2004
- Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2)Human Genetics, 2002
- Steatohepatitis: A tale of two “hits”?Gastroenterology, 1998
- β-Cell Dysfunction Induced by Chronic Hyperglycemia: Current Ideas on Mechanism of Impaired Glucose-Induced Insulin SecretionDiabetes Care, 1992